Information Provided By:
Fly News Breaks for January 12, 2017
TSRO
Jan 12, 2017 | 07:36 EDT
Following TESARO's announcement that it had received a Complete Response Letter, or CRL, from the FDA for the IV formulation of Varubi in chemotherapy-induced nausea and vomiting, Leerink analyst Seamus Fernandez notes that it appears to be only a "temporary setback" and says management expects to be able to address the issue in time to gain approval in the first half of 2017. He reiterates an Outperform rating on the shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO